Itovebi
Biological BioOncology
NDC 50242-084-01
General payments
$359,844
Research payments
$5,948,006
Through program year 2025, $359,844 in general payments and $5,948,006 in research payments were reported against Itovebi (BioOncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $272,613 | 3,129 |
| 2025 | Research | $4,607,512 | 435 |
| 2024 | General | $87,231 | 1,301 |
| 2024 | Research | $1,340,495 | 253 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 74 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,430 general · 688 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.